Lennox International Inc
Change company Symbol lookup
Select an option...
LII Lennox International Inc
XPEV Xpeng Inc
SCHW-J Charles Schwab Corp
BIOT Biotech Acquisition Co
MICR Micron Solutions Inc
WSBF Waterstone Financial Inc
MBRX Moleculin Biotech Inc
STRNY Severn Trent PLC
BRSP Brightspire Capital Inc
DBX Dropbox Inc
Go

Industrials : Building Products | Mid Cap Blend
Company profile

Lennox International Inc. is a provider of climate control solutions. The Company designs, manufactures and markets a range of products for the heating, ventilation, air conditioning and refrigeration (HVACR) markets. The Company operates through three segments: Residential Heating & Cooling, Commercial Heating & Cooling and Refrigeration. Residential Heating & Cooling segment manufactures and markets a range of furnaces, air conditioners, heat pumps, packaged heating and cooling systems, indoor air quality equipment, comfort control products, replacement parts and supplies and related products. Commercial Heating & Cooling segment manufactures and sells unitary heating and cooling equipment used in light commercial applications, such as low-rise office buildings, restaurants, retail centers, churches and schools. Refrigeration segment manufactures and markets equipment for the global commercial refrigeration markets under the Heatcraft Worldwide Refrigeration name.

Closing Price
$222.67
Day's Change
0.16 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
226.74
Day's Low
220.09
Volume
(Below Average)
Volume:
369,434

10-day average volume:
423,298
369,434

Cybin Announces Results of Shareholders' Meeting

5:05 pm ET August 15, 2022 (BusinessWire) Print

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 15, 2022 (the "Meeting"). There were 71 shareholders represented in person or by proxy at the Meeting holding 47,019,721 common shares, representing 28.3% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:

1. Appointment of Auditor

Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at remuneration to be fixed by the directors of Cybin. Voting results are set out below:

 Votes ForVotes Withheld
--------  -------------
  #    %      #      %
---- ---- ------- ------

2. Election of Directors

Each of the nominees for election as director listed in Cybin's management information circular dated July 13, 2022 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below:

 
                                              Votes For                                              Votes Withheld
-------------------- ---------------------------------------------------------  -----------------------------------------------------
 
                                     #                            %                           #                           %
-------------------- ------------------------------- -------------------------- ---------------------------- -------------------------
 Theresa Firestone     20,199,337  98.50   308,536    1.50 
-------------------- ------------------------------- -------------------------- ---------------------------- -------------------------
 Grant Froese          20,146,515  98.24   361,358    1.76 
-------------------- ------------------------------- -------------------------- ---------------------------- -------------------------
 Paul Glavine          20,213,109  98.56   294,764    1.44 
-------------------- ------------------------------- -------------------------- ---------------------------- -------------------------
 Eric Hoskins          20,171,190  98.36   336,683    1.64 
-------------------- ------------------------------- -------------------------- ---------------------------- -------------------------
 Mark Lawson           20,150,317  98.26   357,556    1.74 
-------------------- ------------------------------- -------------------------- ---------------------------- -------------------------

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing "Psychedelics to Therapeutics(TM)" by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Cautionary Notes and Forward Looking Statements

Certain statements in this news release related to the Company may constitute forward-looking statements. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended June 30, 2022 and the Company's annual information form dated June 20, 2022, which are available under the Company's profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Unless otherwise indicated, all dollar amounts in this news release are expressed in Canadian dollars.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220815005677/en/

SOURCE: Cybin Inc.

Investor & Media: 
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com - or - media@cybin.com 

Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
comtex tracking

COMTEX_412329210/1006/2022-08-15T17:05:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.